HIV infection
Infectious disease · 2005–2019
24decisions
18medicines
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| darunavir with cobicistat with emtricitabine and tenofovir alafenamide Treatment of HIV infection in adults and adolescents ≥40kg. The submission indicated use in treatment-naïve patients and treatment-experienced patients already… | Nov 2019 | Recommended with restriction | none received |
| dolutegravir with rilpivirine Treatment of virologically suppressed human immunodeficiency virus (HIV) infected patients. Patients must be virologically suppressed on a previous HIV regimen… | Jul 2018 | Recommended with restriction | none received |
| tenofovir alafenamide / emtricitabine / rilpivirine Treatment of human immunodeficiency virus (HIV) infection in treatment-naïve patients and treatment-experienced patients. | Jul 2016 | Recommended with restriction | none received |
| emtricitabine/tenofovir alafenamide Treatment of human immunodeficiency virus (HIV) infection in treatment-naïve and treatment-experienced patients. | Nov 2016 | Recommended with restriction | no section in document |
| darunavir/cobicistat Treatment of HIV-1 infection in combination with other antiretroviral agents in patients who have experienced virological failure (viral load > 400 copies/mL)… | Nov 2015 | Recommended with restriction | input received |
| dolutegravir + abacavir + lamivudine Treatment of HIV infection in antiretroviral treatment naïve patients aged 12 years or older weighing 40 kg or more, and in patients who have previously… | Nov 2014 | Recommended | none received |
| cobicistat Treatment of HIV-infected patients as a pharmacokinetic enhancer of atazanavir. | Jul 2013 | Not recommended | no section in document |
| cobicistat/elvitegravir/emtricitabine/tenofovir Treatment of HIV infection in treatment-naïve and treatment-experienced patients with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV… | Mar 2013 | Recommended with restriction | no section in document |
| antiretroviral therapy (ART) First-line treatment of HIV infection in antiretroviral treatment naïve patients, with removal of CD4+ cell count restriction (previously required CD4+ <500… | Nov 2013 | Noted | unclear |
| dolutegravir Treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in patients with a CD4 count of less than 500 per… | Nov 2013 | Recommended | no section in document |
| tenofovir disoproxil fumarate with emtricitabine and rilpivirine hydrochloride Treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in patients with CD4 count less than 500 per cubic… | Nov 2011 | Recommended with restriction | no section in document |
| tenofovir disoproxil fumarate with emtricitabine and rilpivirine hydrochloride Treatment of human immunodeficiency virus (HIV) infection in treatment-naïve adult patients with plasma HIV-1 RNA ≤100,000 copies per mL at the start of… | Nov 2011 | Recommended with restriction | no section in document |
| darunavir Treatment of HIV-1 infection in protease inhibitor naïve patients with evidence of HIV replication (viral load >10,000 copies/mL) and/or CD4 cell counts <500… | Jul 2010 | Not recommended | no section in document |
| darunavir Treatment in combination with other antiretroviral agents, co-administered with 100 mg ritonavir once daily, of HIV infection in a protease inhibitor naïve… | Jul 2010 | Not recommended | no section in document |
| tenofovir disoproxil fumarate with emtricitabine and efavirenz Treatment of HIV infection in patients with CD4 cell counts less than 500 per cubic millimetre or viral load greater than 10,000 copies per mL. | Nov 2009 | Recommended with restriction | no section in document |
| raltegravir Treatment, in combination with other antiretroviral agents, of HIV infection in antiretroviral experienced patients with evidence of HIV replication and/or CD4… | Mar 2008 | Recommended with restriction | no section in document |
| darunavir ethanolate Treatment of HIV-1 infection in antiretroviral treatment experienced patients with evidence of viral replication and/or CD4 cell counts <500 per mm³, who have… | Jul 2007 | Recommended with restriction | no section in document |
| darunavir ethanolate Treatment of HIV-1 infection in antiretroviral treatment-experienced patients with evidence of viral replication or CD4 cell counts <500/mm³, who have failed… | Jul 2007 | Recommended with restriction | no section in document |
| tipranavir Treatment of HIV infection in antiretroviral-experienced adults with evidence of HIV replication (viral load >10,000 copies/mL) and/or CD4 cell counts… | Mar 2007 | Recommended with restriction | no section in document |
| tipranavir Treatment, in combination with other antiretroviral agents and co-administered with ritonavir, of HIV infection in antiretroviral experienced adults with… | Jul 2006 | Not recommended | no section in document |
| tipranavir Treatment of HIV infection in antiretroviral experienced patients with resistance to or inability to tolerate multiple protease inhibitors, who have failed… | Jul 2006 | Not recommended | no section in document |
| abacavir sulfate with lamivudine Treatment of HIV infection in combination with other antiretroviral agents in patients over 12 years of age with CD4 cell counts less than 500 per cubic… | Jul 2005 | Recommended | no section in document |
| tenofovir disoproxil fumarate with emtricitabine Treatment of HIV infection in patients with CD4 cell counts of less than 500 per cubic millimetre or viral load of greater than 10,000 copies per mL. | Nov 2005 | Recommended | no section in document |
| tenofovir disoproxil fumarate with emtricitabine Treatment of HIV infection in patients with CD4 cell counts less than 500 per cubic millimetre or viral load greater than 10,000 copies per mL. | Nov 2005 | Recommended | no section in document |
What the PBS pays
$1,554M in government benefit over 2024–25, across 1,362,053 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| tenofovir disoproxil fumarate with emtricitabine and rilpivirine hydrochloride | $189.5M |
| tenofovir disoproxil fumarate with emtricitabine | $183.6M |
| tenofovir disoproxil fumarate with emtricitabine and efavirenz | $183.6M |
| tenofovir alafenamide / emtricitabine / rilpivirine | $181.6M |
| darunavir with cobicistat with emtricitabine and tenofovir alafenamide | $181M |
| cobicistat + elvitegravir + emtricitabine + tenofovir | $178.5M |
| emtricitabine + tenofovir alafenamide | $175.6M |
| dolutegravir/rilpivirine | $72.4M |
| dolutegravir + abacavir + lamivudine | $57.1M |
| dolutegravir | $56.6M |
| abacavir sulfate with lamivudine | $39.2M |
| darunavir/cobicistat | $23.1M |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| zidovudineRETROVIR syrup zidovudine 50mg/5mL bottle | 1992 | 3 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 6 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.